New & Noteworthy!

ACC Rockies Chapter Please join your cardiology colleagues at the ACC Rockies Chapter Meeting in Park City, Utah for updates on ACC affairs, the potential new CV Board, and clinical topics such as Genetic and Sports EP, plus a discussion on the growing role of obesity medications in heart failure, and the first-ever Cardiology State-of-the-State report. There will be many opportunities for networking, as well!. For more information and to register, please visit: ACC Rockies Chapter Meeting 2025

ACC Live Courses
For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings

RSS Latest in Cardiology from ACC.org

  • And That's a Wrap! ACC.26: An ACPC Perspective From a First-Time Attendee
    Attending the American College of Cardiology Annual Scientific Session 2026 (ACC.26) for the first time as a trainee in pediatrics was an eye-opening and astonishing experience.
  • ACC Practice Made Perfect: How to Get Your Start in Advocacy
    In this episode of ACC’s Practice Made Perfect podcast, Drs. Brenton Bauer and Laura Onderko explore practical strategies for getting started in advocacy, with a particular focus on Fellows in Training and Early Career cardiologists.
  • ACC CardiaCast: ATTR-CM Treatment: Recent Updates
    In this episode, Drs. Ahmad Masri and Kevin Alexander review emerging clinical data in transthyretin amyloid cardiomyopathy (ATTR-CM) presented at the Heart Failure Society of America Annual Scientific Meeting and the American Heart Association Scientific Sessions 2025, including key findings from the ATTRibute-CM and HELIOS-B trials.
  • Is ApoB an Appropriate Cost-Effective Marker For Lipid-Lowering Therapy?
    Apolipoprotein B (apoB) may be used as a cost-effective marker to improve population health and guide lipid-lowering therapy (LLT) in primary prevention, according to a computer simulation study published April 8 in JAMA.
  • Higher CV Risk With Hematological Malignancies Varies By Subtype
    Patients and survivors of hematological malignancies face substantially elevated short- and long-term risk of cardiovascular disease compared with the general population – with risk varying significantly by malignancy subtype, according to a population-based cohort study published April 8 in JACC.